SV Health Investors

Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

AdvanCell is a clinical-stage company developing novel radiopharmaceuticals for cancer treatment. It specializes in attaching alpha-emitting isotopes to molecules that deliver cytotoxic radiation directly to tumors, aiming to provide safe and effective therapies for multiple cancer types.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Enara Bio Limited is a biotechnology company based in Oxford, United Kingdom, specializing in the development of vaccines and immunotherapies for cancer treatment and prevention. Founded in 2016 and previously known as ErVaxx Limited, the company focuses on creating targeted cancer immunotherapies by exploring novel antigens derived from endogenous retroviral DNA sequences. Enara Bio's technology platform enables the identification and assessment of tumor specificity and immunogenic potential, facilitating improved strategies for combating various cancers. Through its innovative approach, the company aims to provide effective therapeutic options for a broad patient population.

SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

Brixton Biosciences is a clinical-stage life sciences company developing therapies for pain management. The company focuses on non-addictive, locally targeted treatments delivered via a drug-free injectable that produces reversible nerve inhibition, aiming to provide long-lasting relief. Its lead approach seeks to extend pain relief from a single injection to thirty to sixty days, reducing reliance on systemic medications and addressing unmet needs in both chronic and acute pain.

BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Vittoria Biotherapeutics is a biotechnology company focused on developing gene-edited T-cell therapies to address unmet medical needs in oncology and autoimmune diseases. It utilizes Senza5 technology to enhance the efficacy, safety, and practical utility of cell-based therapeutics, aiming to lower dosing requirements, ease preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. By expanding the potential applications of T-cell therapies, the company seeks to improve patient outcomes across its therapeutic pipeline and advance next-generation cell-based treatments from research toward clinical use.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Rondo Therapeutics is a biopharmaceutical company based in Hayward, California, specializing in the discovery and development of innovative bispecific antibodies aimed at activating the immune system to combat cancer. Founded in 2021, the company focuses on creating cancer immunotherapies specifically for solid tumor types that do not respond to existing immune checkpoint inhibitors. By addressing areas of unmet medical need, Rondo Therapeutics aims to advance novel therapeutic options for patients facing challenging cancer diagnoses.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.

Zerigo Health develops innovative medical devices that deliver narrowband UVB light therapy for chronic skin conditions such as psoriasis, eczema, and vitiligo. Their flagship product, Clarify Medical, is a connected phototherapy system that enables patients to administer treatments at home under physician prescription, ensuring clinical precision while promoting convenience and empowerment.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Leiters Health is an FDA-registered 503B outsourcing provider specializing in high-quality compounded sterile preparations for ophthalmology and hospital-based services. With nearly a century of experience, the company is dedicated to delivering essential medications to healthcare professionals and their patients. Leiters Health offers a comprehensive portfolio that includes ready-to-administer products such as pre-filled syringes, vials, bags, and injectable compounds, as well as opioid-free surgical pain services and specialized cardioplegic and ophthalmic products. The company's team of experts in sterile pharmaceutical manufacturing and compounding employs robust processes and advanced manufacturing facilities to ensure the highest standards of quality and consistency in their offerings, prioritizing patient safety and trust.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

AavantiBio, Inc. is a biopharmaceutical company focused on developing gene transfer and gene editing therapies aimed at treating rare genetic diseases. Incorporated in 2019 and based in Gainesville, Florida, the company primarily concentrates on Friedreich’s Ataxia, a rare inherited disorder that leads to significant cardiac and central nervous system dysfunction. AavantiBio is committed to transforming the lives of patients suffering from this condition by advancing innovative therapies that address unmet medical needs in the field of genetic disorders. The company’s efforts are directed toward both treatment development and research, with the goal of providing effective solutions for patients facing the challenges of rare diseases.

Alchemab Therapeutics Ltd is a biotechnology company based in London, United Kingdom, focusing on the discovery and development of novel therapeutics aimed at patients with hard-to-treat diseases. Established in 2019 by Uri Laserson and Jane Osbourn, the company utilizes a transformative approach to identify drug targets and build a pipeline of antibody therapeutics. Alchemab's strategy involves harnessing naturally protective antibodies through an unbiased and function-first methodology that employs complementary processes and technologies. This innovative approach aims to provide treatments for various challenging conditions, including hard-to-treat cancers, neurodegenerative disorders, and infectious diseases.

Cellinta Limited is a biotechnology company focused on the research and development of innovative gene therapies aimed at treating cancer. Founded in 2019 and headquartered in London, the company has developed a platform that specializes in identifying regulatory circuits specific to cancer stem cells. This technology allows for the selective elimination of neural stem cells and brain cancers. By utilizing computational tools and patient-derived cancer stem cell models, Cellinta aims to deliver targeted anti-cancer therapies and disrupt multiple pathways critical for tumor growth and immune evasion. Formerly known as Biotech 2 Ltd, the company rebranded to Cellinta Limited in February 2020, reflecting its commitment to advancing cancer treatment through cutting-edge gene therapy solutions.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

CytoMed Therapeutics specializes in developing off-the-shelf immunotherapeutics using gamma delta T cells and natural killer cells to treat various tumors. It also generates induced pluripotent stem cells for cellular medicines.

Zarodex Therapeutics is a biotechnology company that treats dementia and Alzheimer's diseases.

EBT Medical, Inc. is a clinical-stage company based in Boston, Massachusetts, with an additional office in Toronto, Canada. Founded in 2014, the company specializes in developing innovative, non-invasive neuromodulation therapies aimed at treating pelvic health disorders, particularly focusing on patients with overactive bladder. EBT Medical's technology is centered on the Saphenous nerve and is designed to provide discreet treatment options that enable patients to restore pelvic health function without the side effects typically associated with conventional therapies. The company emerged from scientific discoveries made at the University of Toronto and has benefited from a startup incubation program that has fostered numerous successful ventures in the past decade.

Enara Bio Limited is a biotechnology company based in Oxford, United Kingdom, specializing in the development of vaccines and immunotherapies for cancer treatment and prevention. Founded in 2016 and previously known as ErVaxx Limited, the company focuses on creating targeted cancer immunotherapies by exploring novel antigens derived from endogenous retroviral DNA sequences. Enara Bio's technology platform enables the identification and assessment of tumor specificity and immunogenic potential, facilitating improved strategies for combating various cancers. Through its innovative approach, the company aims to provide effective therapeutic options for a broad patient population.

Zerigo Health develops innovative medical devices that deliver narrowband UVB light therapy for chronic skin conditions such as psoriasis, eczema, and vitiligo. Their flagship product, Clarify Medical, is a connected phototherapy system that enables patients to administer treatments at home under physician prescription, ensuring clinical precision while promoting convenience and empowerment.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.

Avrobio is a clinical-stage biotechnology company focused on developing ex vivo lentiviral-based gene therapies to treat rare diseases with a single dose. Its pipeline includes AVR-RD-01 for Fabry disease, AVR-RD-02 for type 1 Gaucher disease, and AVR-RD-03 for Pompe disease.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Pionyr Immunotherapeutics Inc. is a biotechnology company focused on developing innovative cancer immunotherapies that specifically target the tumor microenvironment to enhance the body's antitumor immunity. Founded in 2015 and based in San Francisco, California, Pionyr leverages advanced target discovery and antibody generation platform technologies to create next-generation immuno-oncology therapeutics. The company's proprietary approach, known as Myeloid Tuning™, aims to improve the immune system’s anti-tumor response by precisely altering the cellular composition within the tumor microenvironment. This strategy is designed to enable patients to better combat cancer, particularly when used in conjunction with checkpoint inhibitors.

Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.

PanOptica, Inc. is a biotechnology company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. Founded in 2009 and headquartered in Mount Arlington, New Jersey, PanOptica is advancing its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist, which shows potential as a topical treatment for conditions such as wet age-related macular degeneration and diabetic retinopathy. The company aims to address significant unmet needs in ophthalmology by offering new therapeutic options that can improve vision and enhance the quality of life for patients suffering from debilitating eye diseases. By collaborating with pharmaceutical companies, PanOptica seeks to license and develop innovative treatments that may include enhancements to existing therapies or novel solutions for previously untreatable conditions.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Pionyr Immunotherapeutics Inc. is a biotechnology company focused on developing innovative cancer immunotherapies that specifically target the tumor microenvironment to enhance the body's antitumor immunity. Founded in 2015 and based in San Francisco, California, Pionyr leverages advanced target discovery and antibody generation platform technologies to create next-generation immuno-oncology therapeutics. The company's proprietary approach, known as Myeloid Tuning™, aims to improve the immune system’s anti-tumor response by precisely altering the cellular composition within the tumor microenvironment. This strategy is designed to enable patients to better combat cancer, particularly when used in conjunction with checkpoint inhibitors.

NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing therapeutics based on natural killer T (NKT) cells. Established in 2008, the company focuses on creating a pipeline of first-in-class NKT-based treatments targeting a range of conditions, including sickle cell disease, autoimmune and inflammatory diseases, cancer, asthma, and dermatitis. NKT Therapeutics utilizes a unique biotechnology platform that offers humanized monoclonal antibodies to selectively deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. By leveraging its expertise in the intersection of innate and adaptive immunity, NKT Therapeutics aims to provide innovative solutions for complex health challenges.

CardioKinetix develops transcatheter implants for treating heart failure. Its flagship product is Parachute, a ventricular partitioning device designed to improve overall cardiac function in patients who have experienced a heart attack. The company serves customers primarily in the United States and Europe.

ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, that specializes in developing innovative therapy solutions for patients suffering from obesity and obesity-related metabolic disorders. Founded in 2002, ValenTx focuses on minimally-invasive treatment methods, including an endoluminal bypass therapy that replicates the anatomical changes of the traditional Roux-en-Y gastric bypass procedure. This technology features an adjustable, removable, and replaceable device designed to address conditions such as type-2 diabetes and hypertension, aiming to improve patient outcomes in the management of these chronic health issues.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Avrobio is a clinical-stage biotechnology company focused on developing ex vivo lentiviral-based gene therapies to treat rare diseases with a single dose. Its pipeline includes AVR-RD-01 for Fabry disease, AVR-RD-02 for type 1 Gaucher disease, and AVR-RD-03 for Pompe disease.

Kesios Therapeutics, established in 2012, is a UK-based biopharmaceutical company focused on developing small molecule drugs for haematological malignancies, primarily multiple myeloma. The company's pipeline targets key pathways like NF-κB and GADD45β/MKK7, aiming to address unmet medical needs in oncology.

Founded in 2005, Halscion specializes in developing biocompatible hydrogel scaffolds designed to improve wound healing and reduce scarring. These single-use devices are applied during surgeries at the dermal-subdermal interface of wounds by injection, allowing the patient's own cells to organize and propagate into the wound.

PanOptica, Inc. is a biotechnology company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. Founded in 2009 and headquartered in Mount Arlington, New Jersey, PanOptica is advancing its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist, which shows potential as a topical treatment for conditions such as wet age-related macular degeneration and diabetic retinopathy. The company aims to address significant unmet needs in ophthalmology by offering new therapeutic options that can improve vision and enhance the quality of life for patients suffering from debilitating eye diseases. By collaborating with pharmaceutical companies, PanOptica seeks to license and develop innovative treatments that may include enhancements to existing therapies or novel solutions for previously untreatable conditions.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

VHsquared Ltd. is a biotechnology company focused on developing oral biologics for immuno-inflammatory conditions affecting the gastrointestinal tract. Founded in 2010 and based in Cambridge, United Kingdom, VHsquared utilizes its proprietary Vorabody platform to create engineered domain antibodies that are resistant to degradation in the gut, allowing for effective oral administration. This innovative approach addresses the limitations of conventional antibodies, which are typically broken down in the gastrointestinal system. The company aims to produce a range of functional food products that target gastrointestinal infections and immune-mediated diseases, leveraging advancements in mucosal immunology and microbiota analysis. By developing therapies that are stable, specific, and locally active, VHsquared seeks to provide safer, more effective treatment options for patients with inflammatory bowel diseases and related conditions.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, that specializes in the development of novel therapeutics for skin disorders. Founded in 2011, the company is dedicated to creating innovative treatments for dermatological conditions, particularly atopic dermatitis and acne. Unlike many competitors who primarily focus on reformulating existing medications with limited advancements, Thesan aims to discover and develop new chemical entities that promise substantially improved therapeutic options for patients. This commitment to innovation addresses the growing need for effective solutions in a field that has seen relatively little progress in recent years.

PanOptica, Inc. is a biotechnology company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. Founded in 2009 and headquartered in Mount Arlington, New Jersey, PanOptica is advancing its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist, which shows potential as a topical treatment for conditions such as wet age-related macular degeneration and diabetic retinopathy. The company aims to address significant unmet needs in ophthalmology by offering new therapeutic options that can improve vision and enhance the quality of life for patients suffering from debilitating eye diseases. By collaborating with pharmaceutical companies, PanOptica seeks to license and develop innovative treatments that may include enhancements to existing therapies or novel solutions for previously untreatable conditions.

Deciphera Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for cancer patients. It focuses on kinase biology, leveraging its proprietary switch-control kinase inhibitor platform to create a diverse pipeline of drug candidates. Its lead product, QINLOCK®, is approved in several countries for treating fourth-line gastrointestinal stromal tumors (GIST). The company also has multiple clinical-stage and research-stage programs targeting various cancers.

Doctors of Physical Therapy, founded in 2004 and located in Elgin, Illinois, specializes in providing a comprehensive range of physical therapy services. The company operates clinics and also offers on-site therapy for large employers. Its services encompass injury screening, manual therapies, surgical therapy, fall prevention, vestibular therapy, concussion therapy, sports rehabilitation, and post-operative rehabilitation. In addition, the company addresses chronic pain, pelvic floor issues, pediatric therapy, hand therapy, and functional capacity evaluations. With a focus on personalized treatment plans, Doctors of Physical Therapy aims to meet the diverse needs of its patients, whether through in-clinic, in-home, or online care.

Atopix Therapeutics Limited is a clinical-stage biopharmaceutical company based in Oxford, United Kingdom, focused on developing innovative anti-inflammatory medicines for the treatment of asthma, chronic allergic conditions, and other atopic diseases. Founded in 2012, the company specializes in a novel class of oral anti-allergic medications known as CRTH2 antagonists. Its lead candidate is currently undergoing a Phase 2 clinical trial aimed at addressing moderate to severe atopic dermatitis, with studies being conducted at several prominent dermatology centers across Europe. Atopix Therapeutics operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Kesios Therapeutics, established in 2012, is a UK-based biopharmaceutical company focused on developing small molecule drugs for haematological malignancies, primarily multiple myeloma. The company's pipeline targets key pathways like NF-κB and GADD45β/MKK7, aiming to address unmet medical needs in oncology.

KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule protease inhibitors for diseases with unmet needs. Its primary focus is on hereditary angioedema (HAE) and diabetic macular edema (DME). The company's product portfolio includes KVD001, KVD900, and KVD824, which are in various stages of clinical trials for treating these conditions.

Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, established in 2011. The company specializes in developing innovative medicines aimed at treating hearing disorders, including hearing loss and tinnitus. In addition to its focus on auditory conditions, Autifony is also involved in drug discovery for central nervous system disorders, addressing challenges related to conditions such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By leveraging its platform, the company seeks to alleviate symptoms associated with these disorders and meet the unmet medical needs of patients.

EBR Systems is a medical device company that develops implantable wireless tissue stimulation systems for cardiac rhythm management. It focuses on therapies for heart failure and cardiac arrhythmias, including a wireless left ventricular endocardial pacing system used to deliver pacing stimulation directly inside the left ventricle as part of cardiac resynchronization therapy. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems pursues novel approaches in the field and operates primarily in the United States.

CardioKinetix develops transcatheter implants for treating heart failure. Its flagship product is Parachute, a ventricular partitioning device designed to improve overall cardiac function in patients who have experienced a heart attack. The company serves customers primarily in the United States and Europe.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, that specializes in the development of novel therapeutics for skin disorders. Founded in 2011, the company is dedicated to creating innovative treatments for dermatological conditions, particularly atopic dermatitis and acne. Unlike many competitors who primarily focus on reformulating existing medications with limited advancements, Thesan aims to discover and develop new chemical entities that promise substantially improved therapeutic options for patients. This commitment to innovation addresses the growing need for effective solutions in a field that has seen relatively little progress in recent years.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

VHsquared Ltd. is a biotechnology company focused on developing oral biologics for immuno-inflammatory conditions affecting the gastrointestinal tract. Founded in 2010 and based in Cambridge, United Kingdom, VHsquared utilizes its proprietary Vorabody platform to create engineered domain antibodies that are resistant to degradation in the gut, allowing for effective oral administration. This innovative approach addresses the limitations of conventional antibodies, which are typically broken down in the gastrointestinal system. The company aims to produce a range of functional food products that target gastrointestinal infections and immune-mediated diseases, leveraging advancements in mucosal immunology and microbiota analysis. By developing therapies that are stable, specific, and locally active, VHsquared seeks to provide safer, more effective treatment options for patients with inflammatory bowel diseases and related conditions.

Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

CardioKinetix develops transcatheter implants for treating heart failure. Its flagship product is Parachute, a ventricular partitioning device designed to improve overall cardiac function in patients who have experienced a heart attack. The company serves customers primarily in the United States and Europe.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.